TY - JOUR
T1 - Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease
AU - Tanaka, Kyuto
AU - Kamiishi, Nobufumi
AU - Miyata, Jun
AU - Kabata, Hiroki
AU - Masaki, Katsunori
AU - Ogura-Tomomatsu, Hiromi
AU - Tomomatsu, Katsuyoshi
AU - Suzuki, Yusuke
AU - Fukunaga, Koichi
AU - Sayama, Koichi
AU - Betsuyaku, Tomoko
AU - Asano, Koichiro
N1 - Publisher Copyright:
© 2015 Informa Healthcare USA, Inc.
PY - 2015/5/4
Y1 - 2015/5/4
N2 - Tiotropium bromide, a long-acting anticholinergic agent, improves pulmonary function and quality of life of patients suffering from chronic obstructive pulmonary disease (COPD). We retrospectively examined the factors that determine the long-term persistence with tiotropium bromide. Among 6,301 patients who underwent pulmonary function tests in our pulmonary clinic between 2006 and 2009, 644 met the following criteria: 1) age > 40 years, 2) ≥ 20 pack-years smoking history, and 3) forced expiratory volume in 1 sec/forced vital capacity ratio < 0.7. The clinical information, including the prescription of tiotropium, was obtained from the patients' records. Tiotropium was administered to 255 patients (40%), of whom 48 (19%) discontinued treatment within 1 year, and 65 (25%) discontinued treatment within the median observation period of 32 months. The drug was discontinued because of ineffectiveness in 35 patients (73%), and because of adverse drug effects in 13 patients (27%). Young age, current smoking, absence of respiratory symptoms alleviation, and less severe disease characterized by a) mild airflow limitation, b) mild to moderate emphysema, or c) no exacerbation of COPD during the 1st year of treatment were predictors of drug discontinuation.
AB - Tiotropium bromide, a long-acting anticholinergic agent, improves pulmonary function and quality of life of patients suffering from chronic obstructive pulmonary disease (COPD). We retrospectively examined the factors that determine the long-term persistence with tiotropium bromide. Among 6,301 patients who underwent pulmonary function tests in our pulmonary clinic between 2006 and 2009, 644 met the following criteria: 1) age > 40 years, 2) ≥ 20 pack-years smoking history, and 3) forced expiratory volume in 1 sec/forced vital capacity ratio < 0.7. The clinical information, including the prescription of tiotropium, was obtained from the patients' records. Tiotropium was administered to 255 patients (40%), of whom 48 (19%) discontinued treatment within 1 year, and 65 (25%) discontinued treatment within the median observation period of 32 months. The drug was discontinued because of ineffectiveness in 35 patients (73%), and because of adverse drug effects in 13 patients (27%). Young age, current smoking, absence of respiratory symptoms alleviation, and less severe disease characterized by a) mild airflow limitation, b) mild to moderate emphysema, or c) no exacerbation of COPD during the 1st year of treatment were predictors of drug discontinuation.
KW - Anticholinergic therapy
KW - Long-term therapy
KW - Tachyphylaxis
KW - Treatment effectiveness
KW - Treatment tolerability
UR - http://www.scopus.com/inward/record.url?scp=84933502524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933502524&partnerID=8YFLogxK
U2 - 10.3109/15412555.2014.933795
DO - 10.3109/15412555.2014.933795
M3 - Article
C2 - 25093464
AN - SCOPUS:84933502524
VL - 12
SP - 234
EP - 242
JO - COPD: Journal of Chronic Obstructive Pulmonary Disease
JF - COPD: Journal of Chronic Obstructive Pulmonary Disease
SN - 1541-2555
IS - 3
ER -